Achmea Investment Management B.V. Buys 12,627 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Achmea Investment Management B.V. lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 52.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,746 shares of the biotechnology company's stock after purchasing an additional 12,627 shares during the quarter. Achmea Investment Management B.V. owned 0.08% of United Therapeutics worth $12,965,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of UTHR. Wealthfront Advisers LLC increased its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the last quarter. World Investment Advisors LLC purchased a new stake in United Therapeutics during the third quarter valued at $139,206,000. FMR LLC increased its position in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after acquiring an additional 314,004 shares during the last quarter. AustralianSuper Pty Ltd increased its position in United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after acquiring an additional 161,751 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company's stock valued at $89,532,000 after acquiring an additional 123,929 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have commented on the company. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $1.85 during mid-day trading on Friday, reaching $307.24. The company's stock had a trading volume of 494,807 shares, compared to its average volume of 444,109. The stock has a fifty day moving average of $349.77 and a two-hundred day moving average of $358.54. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The firm has a market capitalization of $13.80 billion, a PE ratio of 13.49, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the prior year, the company earned $4.36 earnings per share. Analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company's stock, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 116,464 shares of company stock valued at $42,396,244. Insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.